+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
SENORES

Senores Pharmaceuticals Share Price

₹1,477.70 -13.7 (-0.92%)
New 52W High in past week

14 Aug, 2026 3:52 PM (IST)

Senores Pharmaceuticals live price: ₹1,477.70. It opened at ₹1,491 vs previous close ₹1,491; intraday high/low: ₹1,510/₹1,470. The 50 & 200 DMA stand at ₹1,316.50/₹1,018.90.

Senores Pharmaceuticals Performance

  • Today's Low
  • ₹1,470
  • Today's High
  • ₹1,510
  • 52 Week Low
  • ₹662
  • 52 Week High
  • ₹1,515
  • Open Price₹1,491
  • Previous Close₹1,491
  • Volume105,560
  • 50 DMA₹1,316.50
  • 100 DMA₹1,184.10
  • 200 DMA₹1,018.90

Senores Pharmaceuticals Chart

Investment Returns

  • Over 1 Month + 1.78%
  • Over 3 Month + 54.79%
  • Over 6 Month + 88.59%
  • Over 1 Year + 118.84%

Smart Investing Starts Here Start SIP with Senores Pharmaceuticals for Steady Growth!

Invest Now

Senores Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 53.9
  • PEG Ratio
  • 0.6
  • Market Cap Cr
  • 6,805
  • P/B Ratio
  • 7.3
  • Average True Range
  • 56.4
  • EPS
  • 27.4
  • Dividend Yield
  • 0
  • MACD Signal
  • 35
  • RSI
  • 64.5
  • MFI
  • 49.37

Latest Stock News Updates

Senores Pharmaceuticals Ltd - 544319 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhananjay Barot

Senores Pharmaceuticals Ltd - 544319 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ashokkumar Vijaysinh Barot

Senores Pharmaceuticals Ltd - 544319 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

Senores Pharmaceuticals Limited has informed the Exchange regarding the Scrutinzer Report dated August 04, 2026

Senores Pharmaceuticals Financials

Senores Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,477.70
-13.7 (-0.92%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹1,398.90
  • 50 Day
  • ₹1,316.50
  • 100 Day
  • ₹1,184.10
  • 200 Day
  • ₹1,018.90

Resistance and Support

1485.9 Pivot Speed
  • R3 1,541.50
  • R2 1,525.70
  • R1 1,501.70
  • S1 1,461.90
  • S2 1,446.10
  • S3 1,422.10

Senores Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-07-27 Quarterly Results
2026-05-14 Audited Results
2026-01-20 Quarterly Results & Others To consider other business matters.
2026-01-07 Others Inter alia, 1. To consider and evaluate proposals for raising funds by way of issue of convertible warrants on preferential basis to the promotors/promoter group.
2025-11-06 Quarterly Results

Senores Pharmaceuticals Shareholding Pattern

45.82%
37.78%
6.62%
6.56%
3.21%

About Senores Pharmaceuticals

Senores Pharmaceuticals is engaged in the business of manufacturing, marketing and trading of pharmaceuticals and allied products and also providing management and consultancy services. View More
  • NSE Symbol
  • SENORES
  • BSE Symbol
  • 544319
  • ISIN
  • INE0RB801010

Similar Stocks to Senores Pharmaceuticals

Senores Pharmaceuticals FAQs

Senores Pharmaceuticals share price is ₹1,477 As on 15 August, 2026 | 13:59

The Market Cap of Senores Pharmaceuticals is ₹6805.3 Cr As on 15 August, 2026 | 13:59

The P/E ratio of Senores Pharmaceuticals is 53.9 As on 15 August, 2026 | 13:59

The PB ratio of Senores Pharmaceuticals is 7.3 As on 15 August, 2026 | 13:59

The 52 week High & Low of Senores Pharmaceuticals is ₹1514.8/₹662.4 respectively As on 15 August, 2026 | 13:59

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23